Board logo

subject: Oncology Market Forecast to 2015: Brand Spending and Development Opportunities [print this page]


Oncology Market Forecast to 2015: Brand Spending and Development Opportunities

Oncology Market Forecast to 2015 : Brand Spending and Development Opportunities

Chart the future of the global oncology market

Explore the fiercely competitive oncology market with the most comprehensive resource available. Augment or build your models with deep, meticulously researched data - and expand your understanding of different drugs, classes and sub-classes.

Equip your team with 119 brand profiles, all of which contain painstaking detail:

Historical and projected sales from 2006-2015

Current and projected approvals

Critical clinical trials to watch

Analysis that places each drug in context against key competitors and market events

Patent, generics and litigation information

After scouring the profiles, gauge your resource levels: Brand spending data tracks real-world dollars for promotion, medical affairs, market access and more - information you won't find anywhere else.

Give your teams all the oncology market research they need to make critical product decisions!

Products Profiled in Report

Alkylating Agents

Eloxatin (oxaliplatin) (Sanofi-Aventis)

Picoplatin (Poniard)

Temodar (temozolomide) (Merck)

Treanda (bendamustine) (Cephalon)

Antimetabolites

Alimta (pemetrexed) (Eli Lilly)

Clolar/Evoltra (clofarabine) (Genzyme, Bioenvision)

Dacogen (Eisai, Johnson & Johnson)

Fludara (fludarabine phosphate) (Genzyme)

Folotyn (PDX) (Allos Therapeutics)

Gemzar (gemcitabine hydrochloride) (Eli Lilly)

Vidaza (azacitine) (Celgene)

Xeloda (capecitabine) (Roche)

Antimitotics

Abraxane (paclitaxel albumin) (Abraxis)

EPO906 (Novartis)

Ixempra (ixabepilone) (BMS)

Larotaxel (XRP9881) (Sanofi-Aventis)

Taxol (paclitaxel) (BMS)

Taxotere (docetaxel) (Sanofi-Aventis)

Anthracycline Antibiotics

Doxil/Caelyx (doxorubicin) (J&J, Merck)

Ellence (epirubicin) (Pfizer)

Antihormonal Drugs

Abiraterone (CB7630) (J&J, Cougar)

Arimidex (anastrozole) (AstraZeneca)

Aromasin (exemestane) (Pfizer)

Casodex (bicalutimide) (AstraZeneca)

Faslodex (fulvestrant) (AstraZeneca)

Femara (letrozole) (Novartis)

Lupron (leuprolide) (Abbott Labs)

MDV3100 (Astellas, Medivation)

Ostarine (acetamidoxolutamide) (Merck, GTx)

Pasireotide (SOM230) (Novartis)

Zoladex (goserelin) (AstraZeneca, Biovail)

Immunostimulants

Allovectin-7 (Vical, AnGes)

Cervarix (GSK)

Gardasil (Merck)

Intron-A (Merck)

Mozobil (plerixafor) (Genzyme)

PegIntron (Merck)

Provenge (Dendreon)

R3484 (Roche, Transgene)

Stimuvax (Merck KGaA, Oncothyreon)

Monoclonal Antibodies

Arzerra (ofatumumab) (GSK, GenMab)

Avastin (bevacizumab) (Roche, Chugai)

Campath (alemtuzumab) (Genzyme)

Erbitux (cetuximab) (Eli Lilly, BMS, Merck)

Herceptin (Roche)

IMC-11F8 (Eli Lilly)

Ipilimumab (BMS)

Lintuzumab (SGN-33) (Seattle Genetics)

Omnitarg (pertuzumab) (Roche)

Prolia (denosumab) (Amgen,GSK, Daiichi Sankyo)

Ramucirumab (IMC-1121B) (Eli Lilly)

Rituxan (rituximab) (Roche)

Vectibix (panitumumab) (Amgen)

Conjugates

Brentuximab vedotin (Seattle Genetics)

Inotuzumab ozogamicin (Pfizer)

Mylotarg (gemtuzumab ozogamicin) (Pfizer)

For more information kindly visit

http://www.bharatbook.com/detail.asp?id=81401&rt=Oncology-Market-Forecast-to-2015-Brand-Spending-and-Development-Opportunities.html

OR Contact us at

Bharat Book Bureau

207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.

Phone : +91 22 2757 8668 / 2757 9438

Fax : +91 22 2757 9131

E-mail : info@bharatbook.com

Website : www.bharatbook.com




welcome to loan (http://www.yloan.com/) Powered by Discuz! 5.5.0